MX2019010541A - Compuestos de imidazo-piperidina fusionada como inhibidores de jak. - Google Patents

Compuestos de imidazo-piperidina fusionada como inhibidores de jak.

Info

Publication number
MX2019010541A
MX2019010541A MX2019010541A MX2019010541A MX2019010541A MX 2019010541 A MX2019010541 A MX 2019010541A MX 2019010541 A MX2019010541 A MX 2019010541A MX 2019010541 A MX2019010541 A MX 2019010541A MX 2019010541 A MX2019010541 A MX 2019010541A
Authority
MX
Mexico
Prior art keywords
compounds
jak inhibitors
piperidine
fused imidazo
imidazo
Prior art date
Application number
MX2019010541A
Other languages
English (en)
Inventor
R Fatheree Paul
Smith Cameron
d e sullivan Steven
Jean Van Orden Lori
E L Brandt Gary
A Kleinschek Melanie
D Crater Glenn
Original Assignee
Theravance Biopharma R&D Ip Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theravance Biopharma R&D Ip Llc filed Critical Theravance Biopharma R&D Ip Llc
Publication of MX2019010541A publication Critical patent/MX2019010541A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Los compuestos de fórmula (I): (ver fórmula I) donde las variables se definen en la memoria descriptiva, o una sal farmacéuticamente aceptable del mismo, son útiles como inhibidores de la quinasa JAK. También se proveen composiciones farmacéuticas que comprenden tales compuestos, métodos para usar tales compuestos para tratar procesos y enfermedades respiratorias, e intermediarios útiles para preparar tales compuestos.
MX2019010541A 2017-03-09 2018-03-08 Compuestos de imidazo-piperidina fusionada como inhibidores de jak. MX2019010541A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762469073P 2017-03-09 2017-03-09
PCT/US2018/021492 WO2018165395A1 (en) 2017-03-09 2018-03-08 Fused imidazo-piperidine jak inhibitors

Publications (1)

Publication Number Publication Date
MX2019010541A true MX2019010541A (es) 2019-10-21

Family

ID=61683956

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2019010541A MX2019010541A (es) 2017-03-09 2018-03-08 Compuestos de imidazo-piperidina fusionada como inhibidores de jak.
MX2019010539A MX2019010539A (es) 2017-03-09 2018-03-08 Compuestos de imidazo-piperidina fusionada que contienen una amida heterociclica de 4 miembros como inhibidores de jak.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2019010539A MX2019010539A (es) 2017-03-09 2018-03-08 Compuestos de imidazo-piperidina fusionada que contienen una amida heterociclica de 4 miembros como inhibidores de jak.

Country Status (20)

Country Link
US (10) US10196393B2 (es)
EP (2) EP3592742B1 (es)
JP (2) JP7134990B2 (es)
KR (2) KR102533646B1 (es)
CN (2) CN110461839B (es)
AR (2) AR111242A1 (es)
AU (2) AU2018231035B2 (es)
BR (2) BR112019018649A2 (es)
CA (1) CA2997772A1 (es)
DK (1) DK3592742T3 (es)
EA (2) EA037748B1 (es)
ES (1) ES2882186T3 (es)
IL (2) IL268689B2 (es)
MX (2) MX2019010541A (es)
PH (2) PH12019501941A1 (es)
PT (1) PT3592742T (es)
SG (2) SG11201907544VA (es)
TW (2) TWI779016B (es)
WO (2) WO2018165395A1 (es)
ZA (2) ZA201905585B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2018005446A (es) 2015-11-03 2018-08-01 Theravance Biopharma R&D Ip Llc Compuestos inhibidores de jak quinasa para el tratamiento de enfermedad respiratoria.
US10556901B2 (en) * 2015-11-03 2020-02-11 Topivert Pharma Limited 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine and 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepine derivatives as Janus kinase inhibitors
JP7134990B2 (ja) 2017-03-09 2022-09-12 セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー 縮合イミダゾ－ピペリジンｊａｋ阻害剤
AR111495A1 (es) 2017-05-01 2019-07-17 Theravance Biopharma R&D Ip Llc Compuestos de imidazo-piperidina fusionada como inhibidores de jak
SG11201909019SA (en) 2017-05-01 2019-10-30 Theravance Biopharma R&D Ip Llc Methods of treatment using a jak inhibitor compound
EP3837253B1 (en) 2018-09-04 2023-06-07 Theravance Biopharma R&D IP, LLC Process for preparing jak inhibitors and intermediates thereof
AR116114A1 (es) * 2018-09-04 2021-03-31 Theravance Biopharma R&D Ip Llc Amidas heterocíclicas de entre 5 y 7 miembros como inhibidores de jak
MX2021002521A (es) * 2018-09-04 2021-04-28 Theravance Biopharma R&D Ip Llc Dimetilaminoazetidinaminas como inhibidores de jak.
CN112955451A (zh) * 2018-10-29 2021-06-11 施万生物制药研发Ip有限责任公司 作为jak抑制剂的2-氮杂双环已烷化合物
AU2020228799A1 (en) 2019-02-25 2021-10-07 Henan Medinno Pharmaceutical Technology Co., Ltd. JAK inhibitor compound and use thereof
CN114007621A (zh) 2019-03-05 2022-02-01 因赛特公司 用于治疗慢性肺同种异体移植物功能障碍的jak1途径抑制剂
CN114901659A (zh) * 2019-11-26 2022-08-12 施万生物制药研发Ip有限责任公司 作为jak抑制剂的稠合嘧啶吡啶酮化合物
JP2023508772A (ja) * 2019-12-30 2023-03-03 路良 Ｊａｋ阻害剤化合物及びその使用
TW202144343A (zh) 2020-03-02 2021-12-01 美商施萬生物製藥研發 Ip有限責任公司 Jak抑制劑化合物之結晶水合物
EP3944859A1 (en) * 2020-07-30 2022-02-02 Assistance Publique Hôpitaux de Paris Method for treating immune toxicities induced by immune checkpoint inhibitors
WO2022178215A1 (en) * 2021-02-19 2022-08-25 Theravance Biopharma R&D Ip, Llc Amino amide tetrahydro imidazo pyridines as jak inhibitors
TW202317550A (zh) * 2021-06-25 2023-05-01 美商施萬生物製藥研發 Ip有限責任公司 作為jak抑制劑之咪唑吲唑化合物

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI262914B (en) 1999-07-02 2006-10-01 Agouron Pharma Compounds and pharmaceutical compositions for inhibiting protein kinases
CA2532800C (en) 2003-07-23 2013-06-18 Exelixis, Inc. Anaplastic lymphoma kinase modulators and methods of use
US20050090529A1 (en) 2003-07-31 2005-04-28 Pfizer Inc 3,5 Disubstituted indazole compounds with nitrogen-bearing 5-membered heterocycles, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation
US7884109B2 (en) 2005-04-05 2011-02-08 Wyeth Llc Purine and imidazopyridine derivatives for immunosuppression
US8648069B2 (en) 2007-06-08 2014-02-11 Abbvie Inc. 5-substituted indazoles as kinase inhibitors
JP2010111624A (ja) 2008-11-06 2010-05-20 Shionogi & Co Ltd Ｔｔｋ阻害作用を有するインダゾール誘導体
CA2756989A1 (en) 2009-04-03 2010-10-07 Douglas Burdi Compounds for treating disorders mediated by metabotropic glutamate receptor 5, and methods of use thereof
JP5822844B2 (ja) 2009-12-21 2015-11-24 サミュメッド リミテッド ライアビリティ カンパニー １Ｈ−ピラゾロ［３，４−ｂ］ピリジンおよびその治療的使用
EP2338888A1 (en) 2009-12-24 2011-06-29 Almirall, S.A. Imidazopyridine derivatives as JAK inhibitors
US8575336B2 (en) * 2011-07-27 2013-11-05 Pfizer Limited Indazoles
EP2771340B1 (en) 2011-10-25 2016-04-13 Sanofi 6-(4-hydroxy-phenyl)-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
PT3077395T (pt) 2013-12-05 2018-01-03 Pfizer Pirrolo[2,3-d]pirimidinilo, pirrolo[2,3-b]pirazinilo e pirrolo[2,3-d]piridinilo acrilamidas
EP3143021B1 (en) 2014-05-14 2019-06-12 Pfizer Inc Pyrazolopyridines and pyrazolopyrimidines
WO2016026078A1 (en) 2014-08-19 2016-02-25 Changzhou Jiekai Pharmatech Co., Ltd. Heterocyclic compounds as erk inhibitors
KR101663277B1 (ko) 2015-03-30 2016-10-06 주식회사 녹십자 TNIK, IKKε 및 TBK1 억제제로서의 피라졸계 유도체 및 이를 포함하는 약학적 조성물
MX2018005446A (es) 2015-11-03 2018-08-01 Theravance Biopharma R&D Ip Llc Compuestos inhibidores de jak quinasa para el tratamiento de enfermedad respiratoria.
US10556901B2 (en) * 2015-11-03 2020-02-11 Topivert Pharma Limited 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine and 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepine derivatives as Janus kinase inhibitors
EP3712152B1 (en) 2015-11-03 2021-01-13 Topivert Pharma Limited 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridine and 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepine derivatives as janus kinase inhibitors
JP7134990B2 (ja) 2017-03-09 2022-09-12 セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー 縮合イミダゾ－ピペリジンｊａｋ阻害剤
AR111495A1 (es) 2017-05-01 2019-07-17 Theravance Biopharma R&D Ip Llc Compuestos de imidazo-piperidina fusionada como inhibidores de jak
SG11201909019SA (en) 2017-05-01 2019-10-30 Theravance Biopharma R&D Ip Llc Methods of treatment using a jak inhibitor compound
SG11201909376TA (en) 2017-05-01 2019-11-28 Theravance Biopharma R&D Ip Llc Crystalline forms of a jak inhibitor compound
KR102032418B1 (ko) 2017-06-15 2019-10-16 한국화학연구원 접합 피리미딘 유도체, 이의 제조방법 및 이를 유효성분으로 포함하는 브루톤티로신 키나제 활성 관련 질환의 예방 또는 치료용 약학적 조성물
AR116114A1 (es) 2018-09-04 2021-03-31 Theravance Biopharma R&D Ip Llc Amidas heterocíclicas de entre 5 y 7 miembros como inhibidores de jak
MX2021002521A (es) 2018-09-04 2021-04-28 Theravance Biopharma R&D Ip Llc Dimetilaminoazetidinaminas como inhibidores de jak.
EP3837253B1 (en) 2018-09-04 2023-06-07 Theravance Biopharma R&D IP, LLC Process for preparing jak inhibitors and intermediates thereof

Also Published As

Publication number Publication date
EA201992126A1 (ru) 2020-02-05
CA2997772A1 (en) 2018-09-09
US10196393B2 (en) 2019-02-05
JP6974487B2 (ja) 2021-12-01
EP3592743A1 (en) 2020-01-15
DK3592742T3 (da) 2021-08-09
ES2882186T3 (es) 2021-12-01
JP7134990B2 (ja) 2022-09-12
BR112019018648A2 (pt) 2020-06-16
US10392386B2 (en) 2019-08-27
KR20190127796A (ko) 2019-11-13
AU2018231035B2 (en) 2021-09-09
CN110382498A (zh) 2019-10-25
WO2018165392A1 (en) 2018-09-13
AU2018231032A1 (en) 2019-09-05
US20190127371A1 (en) 2019-05-02
PH12019501985A1 (en) 2020-10-05
TW201837037A (zh) 2018-10-16
TW201840560A (zh) 2018-11-16
AU2018231032B2 (en) 2021-08-19
AU2018231032A8 (en) 2019-10-17
US20230063643A1 (en) 2023-03-02
TWI754019B (zh) 2022-02-01
CN110461839A (zh) 2019-11-15
US11878977B2 (en) 2024-01-23
ZA201905618B (en) 2021-05-26
US20200181141A1 (en) 2020-06-11
WO2018165395A1 (en) 2018-09-13
BR112019018649A2 (pt) 2020-04-07
EP3592742B1 (en) 2021-05-19
US10208040B2 (en) 2019-02-19
NZ756823A (en) 2021-04-30
US10550118B2 (en) 2020-02-04
AR111241A1 (es) 2019-06-19
IL268689A (en) 2019-10-31
US11254669B2 (en) 2022-02-22
EA037748B1 (ru) 2021-05-18
KR102533646B1 (ko) 2023-05-17
US20180258088A1 (en) 2018-09-13
JP2020510015A (ja) 2020-04-02
IL268689B (en) 2022-10-01
PT3592742T (pt) 2021-07-30
IL268689B2 (en) 2023-02-01
SG11201907840RA (en) 2019-09-27
IL268679B (en) 2021-10-31
US20200216447A1 (en) 2020-07-09
EA037261B1 (ru) 2021-03-01
IL268679A (en) 2019-10-31
US11453668B2 (en) 2022-09-27
US10519153B2 (en) 2019-12-31
US20210269436A1 (en) 2021-09-02
ZA201905585B (en) 2020-05-27
AU2018231035A1 (en) 2019-09-05
SG11201907544VA (en) 2019-09-27
AR111242A1 (es) 2019-06-19
JP2020510010A (ja) 2020-04-02
CN110461839B (zh) 2022-08-23
EA201992128A1 (ru) 2020-01-29
US11667637B2 (en) 2023-06-06
MX2019010539A (es) 2019-10-21
KR102526764B1 (ko) 2023-04-27
PH12019501941A1 (en) 2020-07-06
US20190337945A1 (en) 2019-11-07
US20190119275A1 (en) 2019-04-25
CN110382498B (zh) 2022-07-12
EP3592742A1 (en) 2020-01-15
KR20190127798A (ko) 2019-11-13
TWI779016B (zh) 2022-10-01
US20220289737A1 (en) 2022-09-15
US20180258087A1 (en) 2018-09-13
US10954237B2 (en) 2021-03-23

Similar Documents

Publication Publication Date Title
PH12019501985A1 (en) Fused imidazo-piperidine jak inhibitors
PH12018500828A1 (en) Jak kinase inhibitor compounds for treatment of respiratory disease
PH12017502050A1 (en) Naphthyridine compounds as jak kinase inhibitors
PH12019502264A1 (en) Fused imidazo-piperidine jak inhibitors compound
MX2018013191A (es) Compuestos de pirimidina como inhibidores de la quinasa jak.
SG10201811384TA (en) Mnk inhibitors and methods related thereto
MX2021002521A (es) Dimetilaminoazetidinaminas como inhibidores de jak.
MD4800B1 (ro) Compuşi de aminopirimidinil ca inhibitori de JAK
TN2016000268A1 (en) N-azaspirocycloalkane substituted n-heteroaryl compounds and compositions for inhibiting the activity of shp2.
PH12020500528A1 (en) Pyrimidine compound as jak kinase inhibitor
PH12021550324A1 (en) 5 to 7 membered heterocyclic amides as jak inhibitors
SA519401322B1 (ar) مركبات أريل كربوكساميد غير متجانسة كمثطبات لكيناز بروتين سيرين/ ثريونين متداخل مع المستقبل 2
PH12019502693A1 (en) Heteroaromatic compounds as vanin inhibitors
PH12021551280A1 (en) Heteroaromatic compounds as vanin inhibitors
PH12021550269A1 (en) Heteroaromatic compounds as vanin inhibitors
MX2021006489A (es) Compuestos heteroaromaticos como inhibidores de vanina.
PH12019500198A1 (en) Compounds and compositions and uses thereof
MX2016010272A (es) Derivado de indolona sustituido por pirrol, metodo de preparacion del mismo, composicion que comprende el mismo y uso del mismo.
MX2021006490A (es) Compuestos heteroaromaticos como inhibidores de vanina.
MX2019000542A (es) Derivados de pirazolilaminobenzimidazol como inhibidores de jak.
EA201990686A1 (ru) Нафтиридиновые соединения в качестве ингибиторов jak киназы